Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Income from Continuing Operations (2020 - 2025)

Gain Therapeutics has reported Income from Continuing Operations over the past 6 years, most recently at 17938521.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 17938521.0 for Q4 2025, up 576.05% from a year ago — trailing twelve months through Dec 2025 was 2315003.0 (up 111.34% YoY), and the annual figure for FY2025 was 2315005.0, up 111.34%.
  • Income from Continuing Operations for Q4 2025 was 17938521.0 at Gain Therapeutics, up from 5284373.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for GANX hit a ceiling of 17938521.0 in Q4 2025 and a floor of 8143078.0 in Q2 2024.
  • Median Income from Continuing Operations over the past 5 years was 4544133.5 (2022), compared with a mean of 2410919.65.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 554.57% in 2021 and later skyrocketed 576.05% in 2025.
  • Gain Therapeutics' Income from Continuing Operations stood at 3065025.0 in 2021, then surged by 313.28% to 12667235.0 in 2022, then plummeted by 137.29% to 4723969.0 in 2023, then grew by 20.23% to 3768227.0 in 2024, then skyrocketed by 576.05% to 17938521.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 17938521.0 (Q4 2025), 5284373.0 (Q3 2025), and 5809087.0 (Q2 2025) per Business Quant data.